![List of the 700 largest Biotech Venture Capital Investors [Update 2024]](https://usercontent.one/wp/www.thousandinvestors.com/wp-content/uploads/2022/11/Thousand-Investors-Biotech.png)
This article directly stems from the research process for our global venture capital investors database. Based on this list and our advanced keyword crawler technology, we created a list of venture capital investors that mention biotech investment keywords on their website. The list – offered as an Excel file – is perfectly suited to get in touch with the most relevant investors in the field.
The biotech industry consists of companies that develop pharmaceuticals, medical devices and treatments to combat diseases. This article offers an insight into three interesting biotech investors in the U.S. from our keyword-crawler based biotech investor list.
1. MPM Capital (Cambridge)
MPM Capital is an early-stage investor for biotechnology start-ups. The investments of the Cambridge-based firm are mainly focused on the healthcare sector and, specifically, oncology. Portfolio companies include Dyne Therapeutics, AKTIS Oncology or Iteos Therapeutics. Iteos, for instance, is working on immuno-oncology drugs and Frontier Medicines is developing new medication for previously presumed untreatable targets.
2. Omega Funds (Boston)
Omega Funds was founded in 2004 and has, since then, invested in more than 150 life science companies. The aim of the company is to invest in various businesses in the medical field which focus on rare diseases, oncology, and precision medicine. A few examples of portfolio companies include Achaogen, who develop antibacterial treatments and Icosavax, who research effective vaccines against infectious diseases. Omega Funds targets early venture rounds as well as late-stage public financing.
3. Atlas Venture (Cambridge)
Atlas Venture has a long history of divers investments going back as far as 1980. In 2014 the company decided split into separate firms with Atlas Venture focusing exclusively on the technology sector, aiming to unite experienced entrepreneurs. Their portfolio consists of various investment approaches, ranging from asset-centric product plays to drug discovery platforms. Be Biopharma, for instance, engineers B cells as medicine and Navitor Pharmaceuticals research therapies to target diseases of aging.
Picture Source: Wengang Zhai
